Biofrontera Inc. is launching the RhodoLED XL, a red-light emitting LED lamp.
The RhodoLED XL is approved by the U.S. Food and Drug Administration (FDA) in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of actinic keratoses of mild-to-moderate severity on the face and scalp.
The RhodoLED XL illuminates a larger area in a single on-label Ameluz PDT treatment. It is designed to be simple to maneuver and able to accommodate various patient treatment positions to optimize ease of use.
“We are delighted to introduce the RhodoLED XL lamp to the dermatology community in the US,” says Dr. Hermann Luebbert, CEO of Biofrontera Inc., in a news release. “This new device underscores our commitment to innovation and excellence, providing dermatologists with a powerful tool to deliver superior patient care. The XL lamp’s advanced features and user-friendly design will undoubtedly set a new standard in photodynamic therapy.”
In comparison to Biofrontera’s existing lamp, the RhodoLED XL offers a larger illumination area with five panels compared to one, and additional features such as positioning sensors to ensure the patient receives the optimal energy delivery from the LED array.
Cleaver Dermatology in Missouri and Georgia (pictured above) was the first to have the RhodoLED XL lamp installed.
“We are honored to be the first to integrate the XL lamp into our practice,” says David Cleaver, DO, in Kirksville, MO. “The advanced features and versatility of this device represent a considerable upgrade on what has been available until now and will allow us to provide our patients with the highest standard of care. In addition, we have been very pleased with the level of customer service that the team at Biofrontera has delivered.”
